Regeneron Pharmaceuticals, Inc.(REGN)
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Latest News & Analysis
Regeneron's Hematology Inflection and EYLEA HD Defensibility
ASH 2025 Lynozyfic monotherapy data and EYLEA HD RVO approval validate Regeneron's execution against biosimilar competition.
Regeneron's Gene Therapy Breakthrough Signals Platform Expansion Beyond Antibody Dominance
DB-OTO data published in NEJM validates genetic hearing loss treatment, demonstrating R&D versatility as company diversifies beyond core franchises.
Regeneron Faces Securities Lawsuit: Investor Update
Regeneron Pharmaceuticals faces multiple securities lawsuits amid legal challenges and market pressure. Detailed analysis provided.
Regeneron Pharmaceuticals Faces Legal and Sales Pressure Amidst EYLEA Competition
Intraday update reveals mounting legal challenges, declining EYLEA sales, and heightened competitive pressures affecting REGN.
Regeneron Pharmaceuticals Faces Securities Lawsuit: Investor Deadline Looms
Regeneron (REGN) is embroiled in a securities lawsuit over alleged Eylea pricing violations, with a critical lead plaintiff deadline on March 10, 2025.
Regeneron (REGN) in Crisis: Securities Lawsuit and EYLEA Competition
Regeneron (REGN) faces a securities lawsuit and EYLEA competition. Analysis of allegations, market impact, and strategic responses are crucial for investors.
Regeneron (REGN): Lawsuits, EYLEA Competition, and Gene Therapy Hope
Regeneron faces lawsuits and EYLEA competition, but gene therapy offers hope. Investors must weigh risks and opportunities.
Regeneron (REGN): Legal Battles, Pipeline Hopes, and Investor Outlook
Regeneron faces securities lawsuits over EYLEA sales, while the FDA reviews odronextamab for lymphoma. Competitive pressures and pipeline developments shape investor outlook.
Regeneron (REGN): Lawsuits, FDA Review, and Competitive Challenges
Regeneron (REGN) faces lawsuits amid EYLEA concerns, while an FDA review offers hope. Dupixent remains strong, but competition persists. The future hinges on innovation.
Regeneron: EU Approval and Legal Battles Shape REGN's Future
Regeneron faces securities fraud lawsuits amid positive EU recommendation for Linvoseltamab. EYLEA and Dupixent remain key revenue drivers.
Regeneron Pharmaceuticals: Navigating Legal and Market Headwinds
Regeneron faces securities lawsuits amid market challenges and strategic initiatives. Investors assess potential impacts and the company's ability to navigate headwinds.
Regeneron Pharmaceuticals, Inc.: Strategic Financial & Market Analysis
Detailed analysis of REGN's Q4 results, legal challenges, EYLEA competition, and pipeline innovation underpinned by robust financials.
Regeneron (REGN) Stock Under Pressure: Class Action Lawsuits and Eylea Concerns
Regeneron (REGN) faces lawsuits and Eylea scrutiny, but Dupixent's growth and a strong pipeline offer potential. Investors should weigh risks and opportunities carefully.
Regeneron (REGN): Eylea's Challenge, Dupixent's Promise, and R&D Power
Regeneron navigates Eylea biosimilar competition with Dupixent's growth and strategic R&D investments. Legal challenges and market dynamics shape its outlook.
Regeneron (REGN): Dupixent's Growth vs. Eylea's Challenges - A Financial Analysis
Regeneron (REGN) navigates Dupixent's growth against Eylea's biosimilar challenges. Strategic R&D and collaborations are key for sustained financial health.
Regeneron (REGN): Dupixent's Expansion and Eylea's Resilience
Regeneron navigates market dynamics with Dupixent's COPD approval in Japan and Eylea's resilience against biosimilars. A deep dive into financials and strategic moves.
Regeneron's Mixed Regulatory News: Dupixent Win, EYLEA HD Setback
Regeneron ([REGN](/dashboard/companies/REGN)) sees Dupixent approved for CSU, a new market, while EYLEA HD extended dosing faces FDA setback, impacting competitive positioning.
Regeneron (REGN) Analysis: Strategic Tech Adoption & Pipeline Progress
Regeneron Pharmaceuticals is making strategic moves in genomics and AI while advancing its oncology pipeline. Explore the financial implications.
Regeneron's Strategic Maneuvers: Navigating Clinical Pipeline and Market Dynamics
Regeneron's stock dips slightly despite strong Dupixent data and strategic pipeline moves, highlighting complex investor sentiment.
Regeneron (REGN): Eylea Headwinds & Dupixent's Growth Amid Pipeline Shifts
Regeneron faces a pivotal moment in 2025, navigating Eylea's biosimilar pressures while Dupixent drives growth and new obesity deals reshape its pipeline.
Regeneron's Strategic Evolution: Dupixent's Clinical Wins & Financial Dynamics
Regeneron's 2025 is marked by Dupixent's clinical breakthroughs and strategic financial shifts, impacting its market position and future growth.
Regeneron (REGN): Strategic Moves & Dupixent's Clinical Triumph
Regeneron's strategic pivot: withdrawing 23andMe bid while Dupixent achieves clinical triumph, showcasing disciplined capital allocation and pipeline strength.
Regeneron's Dupixent FDA Approval for Bullous Pemphigoid: Analysis
Regeneron's Dupixent receives FDA approval for Bullous Pemphigoid, marking a significant expansion of its therapeutic reach and reinforcing the company's leadership in biologics.
Regeneron's Strategic Expansion: Dupixent & Obesity Pipeline Fuel Growth
Regeneron's latest FDA approval for Dupixent in bullous pemphigoid and its strategic entry into the obesity market with HS-20094 signal robust future growth.
Regeneron (REGN) Financials: Dupixent & Eylea Competitive Analysis
Deep dive into Regeneron's recent financial performance, Dupixent's surge, the strategic obesity pipeline, and Eylea's resilience amidst competition.
Regeneron Pharmaceuticals Growth Drivers and Strategic Market Positioning | Monexa AI
Explore Regeneron's latest growth catalysts, including Dupixent expansion, Lynozyfic launch, EYLEA challenges, and strategic financial performance insights.
Regeneron Pharmaceuticals Strategic Growth and Financial Analysis Amid Obesity Market Expansion
Regeneron pivots with dual GLP-1/GIP obesity drug HS-20094, counters Eylea sales decline, and bolsters pipeline with Dupixent growth and 23andMe data acquisition.
Regeneron Pharmaceuticals 2025 Update: Lynozyfic Approval, Oncology Expansion & Financial Analysis
Regeneron’s FDA approval of Lynozyfic marks a strategic pivot into oncology, diversifying revenue beyond Eylea amid strong financial fundamentals.
Regeneron Pharmaceuticals: Lynozyfic Approval Drives Growth Amid Oncology and Obesity Pipeline Expansion
Regeneron's Lynozyfic FDA approval marks a strategic milestone, boosting oncology prospects alongside Dupixent sales and obesity pipeline advancements.
Regeneron (REGN) Analysis: Obesity Market Entry & Pipeline Shifts
Regeneron Pharmaceuticals navigates pipeline shifts and strategic expansions, entering the obesity market while managing clinical setbacks. Data-driven analysis reveals financial resilience and future growth drivers.
Regeneron Pharmaceuticals (REGN) Navigates Eylea Decline with Dupixent Growth and Oncology Expansion
Regeneron (REGN) tackles Eylea sales decline through Dupixent expansion, Lynozyfic launch, and pipeline diversification. Insights on financial impact and strategy ahead of Q2 earnings.
Regeneron Pharmaceuticals Q2 2025 Analysis: Dupixent Growth and Strategic Diversification Insights
Explore Regeneron's Q2 2025 financials, Dupixent's growth, Eylea's competitive challenges, and strategic diversification into oncology and obesity markets.
Regeneron Pharmaceuticals Q2 2025 Earnings Beat Expectations: Dupixent Drives Growth Amid Pricing Pressures
Regeneron reports strong Q2 2025 earnings with Dupixent sales surging 22%, outperforming estimates despite drug pricing challenges and competitive pressures.
Regeneron Pharmaceuticals Q2 2025 Update: Dupixent Growth, Eylea Challenges & Pipeline Outlook
Regeneron reports strong Q2 2025 earnings driven by Dupixent and Libtayo growth amid Eylea decline and regulatory hurdles. Pipeline expansion and financials analyzed.
Regeneron (REGN): Q2 Beat, EYLEA Headwinds and Capital Allocation
Regeneron reported a Q2 EPS beat (non-GAAP $12.89) and revenue recovery, but EYLEA legacy erosion from Vabysmo and biosimilars forces a commercial pivot amid heavy buybacks.
Regeneron Pharmaceuticals: Analyzing Recent Financials & Strategic Moves
Exploring Regeneron's latest financial results, strategic pipeline moves, and clinical trial outcomes, and their impact on the company's market position and future growth.
Regeneron (REGN): Earnings Strength Meets EYLEA HD Regulatory Overhang
Q2 beats (EPS **$12.89** vs est. **$8.43**) and Dupixent momentum clash with an FDA extension for EYLEA HD; strong cash generation masks near‑term execution risk.
Regeneron (REGN): Pipeline Catalysts Offset EYLEA Timing Risk
Regeneron beat August estimates by +52.92% and posted positive Phase 3 cemdisiran data; strong cash flow funds buybacks but EYLEA HD CMC delays keep near-term upside constrained.
Regeneron (REGN): Earnings Beat, Cemdisiran Win and a Strategy Re-Weighted Toward R&D
Regeneron’s Aug. 2025 EPS beat (+52.9%) and a Phase‑3 cemdisiran win reset the runway — but rising R&D intensity, margin compression and data‑dependent catalysts define near‑term risk.
Regeneron (REGN): Dupixent Strength vs. Legal Overhang — Financials, Risks, and Strategy
Dupixent momentum (+22% YoY Q2 2025) and FY2024 cash flow strength contrast with an active DOJ False Claims Act case and a shareholder probe that add governance risk.
Regeneron Pharmaceuticals Secures Dual FDA Wins as Pipeline Diversification Accelerates
Libtayo achieves first-in-class status for skin cancer while Evkeeza expands cardiovascular reach, signaling portfolio evolution beyond core franchises.